cancer

CRISPR eyes autoimmune disease in revamp of cell therapy plans
CRISPR eyes autoimmune disease in revamp of cell therapy plans
BioPharma Dive
CRISPR Therapeutics
cell therapy
autoimmune disease
cancer
Flag link:
AstraZeneca, AI biologics firm Absci tie up on cancer drug
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Reuters
AstraZeneca
Absci
artificial intelligence
cancer
Flag link:
Merck turns to Acclinate to increase African American participation in cancer trials
Merck turns to Acclinate to increase African American participation in cancer trials
Fierce Biotech
Merck
clinical trials
clinical trial diversity
Acclinate
cancer
digital health
Flag link:
BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor
BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor
BioSpace
BeiGene
Ensem
EXT-197
cancer
Flag link:
Gilead Oncology’s brand refresh takes back the possibilities cancer steals
Gilead Oncology’s brand refresh takes back the possibilities cancer steals
Medical Marketing and Media
Gilead Oncology
branding
oncology
cancer
Flag link:
FDA's oncology office uses advisory committee to spotlight timely accelerated approval confirmation
FDA's oncology office uses advisory committee to spotlight timely accelerated approval confirmation
Fierce Pharma
FDA
regulatory
oncology
cancer
accelerated approvals
Acrotech Biopharma
Flag link:
Nouscom raises $72m in Series C financing round to develop cancer vaccines
Nouscom raises $72m in Series C financing round to develop cancer vaccines
Clinical Trials Arena
Nouscom
funding
cancer
cancer vaccines
Flag link:
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Pharma Voice
Cidara
JNJ
immunotherapy
drug-Fc conjugates
cancer
Flu
Flag link:
Moderna, Caris Life Team Up to Advance mRNA-Based Oncology Therapeutics
Moderna, Caris Life Team Up to Advance mRNA-Based Oncology Therapeutics
Marketwatch
Moderna Therapeutics
Caris Life Sciences
oncology
cancer
MRNA
Flag link:
ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data
ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data
Fierce Biotech
AstraZeneca
cancer
oncology
bispecifics
Flag link:
Merck discontinues some cancer drug development with China's Sichuan Kelun
Merck discontinues some cancer drug development with China's Sichuan Kelun
Reuters
Merck
Sichuan Kelun Pharmaceutical
cancer
oncology
Flag link:
Charles River offers clients new database for pediatric oncology research
Charles River offers clients new database for pediatric oncology research
Biopharma Reporter
Charles River Labs
oncology
pediatric
cancer
data
Flag link:
Myriad touts the role of genetic testing in identifying cancer risks
Myriad touts the role of genetic testing in identifying cancer risks
Medical Marketing and Media
Myriad Genetics
MyRisk
genetic testing
cancer
diagnostics
Medtech
Flag link:
ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists
ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists
Fierce Pharma
ESMO
oncology
cancer
Europe
conferences
Flag link:
Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA
Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA
BioSpace
Relay Therapeutics
cancer
Inflation Reduction Act
Flag link:
BioNTech Inks Potential $1B Deal with MediLink for Cancer-Focused ADCs
BioNTech Inks Potential $1B Deal with MediLink for Cancer-Focused ADCs
BioSpace
BioNTech
MediLink
cancer
antibody-drug conjugate
Flag link:
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
CP Wire/Businesswire
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
cancer
Krazati
Flag link:
Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Harbinger Health foreshadows launch of blood-based cancer screening platform with $140M VC round
Fierce Biotech
Harbinger Health
Medtech
diagnostics
cancer
funding
liquid biopsy
Flag link:
Amgen unveils Partners of Choice oncology network
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Amgen
expert panels
oncology
cancer
Flag link:
Kinnate lays off 70% of staff, pulls back from programs to save cash after data disappointment
Kinnate lays off 70% of staff, pulls back from programs to save cash after data disappointment
Fierce Biotech
Kinnate Biopharma
cancer
layoffs
exarafenib
Flag link:

Pages